Serum HMGB-1 released by ferroptosis and necroptosis as a novel potential biomarker for systemic lupus erythematosus.

Biomarker Ferroptosis HMGB-1 Necroptosis SLE

Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
10 Aug 2024
Historique:
received: 10 06 2024
revised: 16 07 2024
accepted: 04 08 2024
medline: 12 8 2024
pubmed: 12 8 2024
entrez: 11 8 2024
Statut: aheadofprint

Résumé

High mobility group box proterin-1 (HMGB-1) is a multifunctional protein that can be released by various programmed cell deaths (PCDs), such as necroptosis and ferroptosis. PCDs play a critical role in the pathogenesis of systemic lupus erythematosus (SLE). However, the role of HMGB-1 in the process of SLE remains unclear. This study aims to demonstrate the potential diagnosing role of serum HMGB-1 in SLE that released by necroptosis and ferroptosis. We found that the serum levels of HMGB-1, receptor-interacting protein kinase 3 (RIPK3) /mixed lineage kinase domain-like protein (MLKL) related with necroptosis, and metabolites associated with ferroptosis were significantly upregulated in SLE patients compared to HC individuals. These serum levels were positively correlated with SLE disease activity. Additionally, the serum level of HMGB-1 showed a strong positive correlated with the levels of RIPK3/MLKL and ferroptosis metabolites. Moreover, the serum level of HMGB-1 was correlated with renal involvement and high-antinuclear antibodies (ANA) titer. After SLE serum and interferon γ (IFN-γ) treatment in vitro, the level of necroptosis and ferroptosis markers were activated and HMGB1 was released both in HEK293 and HK2 cells. Clinically, HMGB-1 was considered as a significant independent risk factor in SLE serum by binary logistic assay. Notably, HMGB-1 exhibited outstanding diagnostic ability for SLE by the area under the curve (AUC) in receiver operating characteristic (ROC) curve analysis. Taken together, our study indicates that the serum level of HMGB-1 is a promising biomarker for the diagnosis and monitoring of SLE.

Identifiants

pubmed: 39128419
pii: S1567-5769(24)01407-3
doi: 10.1016/j.intimp.2024.112886
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112886

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Guowang Zhao (G)

Department of Rheumatology and Clinical Immunology, The Second Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunming 650101, China.

Xingzi Wang (X)

Department of Nephrology, Yueyang Central Hospital, Hunan Province, Yueyang 414000, China.

Hongtao Lei (H)

School of Public Health, Kunming Medical University, Yunnan Province, Kunmin 650500, China.

Ni Ruan (N)

Department of Rheumatology and Clinical Immunology, The Second Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunming 650101, China.

Bo Yuan (B)

Department of organ transplantation department, The First Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunmin 650033, China.

Songbiao Tang (S)

Department of Rheumatology, Yueyang Central Hospital, Hunan Province, Yueyang 414000, China.

Nan Ni (N)

Department of Rheumatology and Clinical Immunology, The Second Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunming 650101, China.

Zan Zuo (Z)

Department of Gastroenterology, First People's Hospital of Yunnan Province, Yunnan Province, Kunming 650033, China.

Linting Xun (L)

Department of Gastroenterology, First People's Hospital of Yunnan Province, Yunnan Province, Kunming 650033, China.

Mei Luo (M)

Department of Gastroenterology, First People's Hospital of Yunnan Province, Yunnan Province, Kunming 650033, China.

Qiuyan Zhao (Q)

Department of Gastroenterology, First People's Hospital of Qujing, Yunnan Province, Qujing, China. Electronic address: zqiuyls@163.com.

Jialong Qi (J)

Department of Gastroenterology, First People's Hospital of Yunnan Province, Yunnan Province, Kunming 650033, China; Yunnan Provincial Key Laboratory of Clinical Virology, The First People's Hospital of Yunnan Province, Kunming, Yunnan,650032, China; Yunnan Provincial Key Laboratory of Birth Defects and Genetic Diseases, First People's Hospital of Yunnan Province, Kunming, Yunnan, 650032, China; Yunnan Clinical Research Center for Geriatric Disorders, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology, Kunming, Yunnan, 650032, China. Electronic address: 962992598@qq.com.

Ping Fu (P)

Department of Rheumatology and Clinical Immunology, The Second Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunming 650101, China. Electronic address: 19100791112@163.com.

Classifications MeSH